China

MegaRobo Secures $200 Mn to Expand AI-Powered Lab Automation and Smart Manufacturing

Nov 19, 2026 | By Nguyen Minh

MegaRobo Secures $200 Mn

China-based laboratory automation company MegaRobo has Secures nearly US$200 million in a new funding round led by the Oman Investment Authority. The investment will support the company's research and development, product expansion, and international partnerships as it expands its AI-powered automation technologies across laboratories and manufacturing facilities.

Existing investors, including Asia Investment Capital, Granite Asia, and Sinovation Ventures, also participated in the round. New investors include CMB International, Suzhou Venture Capital, and Sanjiang Zhaoshang Group.

MegaRobo's AI-Powered Automation Technology

MegaRobo develops automation systems for life sciences research and advanced manufacturing. Its solutions focus on two main areas: smart laboratories and smart manufacturing.

In life sciences, the company helps research organisations automate laboratory experiments and improve research efficiency. Its manufacturing solutions support industries such as semiconductors, optical interconnects, and display production.

Funding to Support Research and Global Expansion

The latest funding will help MegaRobo strengthen its core research and development activities and expand its business through partnerships in China, Europe, North America, the Middle East, and Southeast Asia.

The company aims to address a growing challenge in AI-powered scientific research: the availability of high-quality and reliable experimental data.

By automating laboratory processes, MegaRobo aims to help scientists generate research data more efficiently and support the development of AI applications in drug discovery and other scientific fields.

Kunpeng Lab Advances AI-Driven Drug Discovery

MegaRobo's Kunpeng Lab platform combines AI-based experiment planning with robotic laboratory execution. Its system uses two AI-driven components: one helps design experiments using scientific literature, while the other manages their execution through robotic equipment.

This process creates a continuous cycle of experiment planning, automated testing, result validation, and data collection.

According to the company, its platform has advanced 31 drug-discovery pipelines in seven months, highlighting its potential to support research and pharmaceutical development.

MegaRobo's Growth and Market Position

MegaRobo has Secures to US$600 million in total funding since its founding. As of June 2025, the company reported an order backlog of US$206.3 million and had delivered automation infrastructure to more than 500 customers.

Its customer base includes multinational pharmaceutical companies, contract research organisations (CROs), and scientific research institutions.

The company operates in a competitive market that includes established laboratory technology providers such as Tecan and Thermo Fisher Scientific. Its ability to expand its customer base and deliver scalable automation products will be important for its long-term growth.

About MegaRobo

About MegaRobo company

MegaRobo is a China-based technology company specialising in laboratory automation and smart manufacturing solutions. The company develops robotic systems and AI-powered platforms for life sciences research, pharmaceutical development, and advanced manufacturing.

Its technology aims to automate complex laboratory workflows, improve research productivity, and generate high-quality experimental data for scientific applications.

Read Also - FOMO Pay Partners with Anchorage Digital to Expand US Stablecoin Payment Infrastructure

Recommended Stories for You